Clinical Trials Logo

Filter by:
NCT ID: NCT06107114 Not yet recruiting - Clinical trials for Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable

Cetuximab+Zimberelimab in Combination With Cisplatin and Nab-paclitaxel in Resctable Head and Neck Squamous Cell Carcinoma

CZCNRHNSCC
Start date: December 1, 2023
Phase: Phase 2
Study type: Interventional

This study is a single arm phase ll trial including 52 patients with T2N2-3M0#T3-4N0-3M0 (III-V) head and neck squamous cell carcinoma(HNSCC) eligible forresection, who receive Cetuximab+ Zimberelimab combined with cisplatin and Nab.paclitaxel.This proposed study will evaluate the efficacy and safety of preoperative administration of Cetuximab+ Zimberelimab combined with chemotherapy in Head and Neck Squamous Cell Carcinoma(HNSCC) who are about to undergo surgery.

NCT ID: NCT06105203 Not yet recruiting - Rectal Neoplasms Clinical Trials

RATME vs LATME in Middle and Low Rectal Cancer

Start date: January 1, 2024
Phase: N/A
Study type: Interventional

This is a multicenter, superior, randomized controlled trial designed to compare Robotic-assisted total mesorectal excision (RATME) and laparoscopic-assisted total mesorectal excision (LATME) for middle and low rectal cancer. The primary endpoint is the incidence of intersphincteric resection (ISR). The secondary outcomes are coloanal anastomosis (CAA), conversion to open, conversion to transanal TME (TaTME), incidence of abdominoperineal resection (APR), postoperative morbidity and mortality within 30 days after surgery, pathological outcomes, long-term survival outcomes, functional outcomes, and quality of life.

NCT ID: NCT06105008 Not yet recruiting - Breast Neoplasms Clinical Trials

Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer

Start date: December 20, 2024
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety and tolerability of RC48-ADC with JS001 compared with RC48-ADC in endocrine-resistant hormone receptor (HR) positive, human epidermal growth factor receptor (HER)2-low advanced breast cancer.

NCT ID: NCT06103149 Not yet recruiting - Emotional Distress Clinical Trials

The Role of Cognitive Flexibility in Mindfulness Intervention: a Functional Near-infrared Spectroscopy Study

Start date: October 28, 2023
Phase: N/A
Study type: Interventional

This study hopes to: explore the relationship between mindfulness mediation experiences and emotional distress and cognitive flexibility levels. explore whether mindfulness interventions can significantly alleviate individual emotional distress and improve cognitive flexibility level. explore whether cognitive flexibility is a mediator in mindfulness intervention to alleviate emotional distress, and to meet the principles of mechanism. explore the brain functional characteristics and changes during the mindfulness intervention.

NCT ID: NCT06102447 Not yet recruiting - Clinical trials for Head and Neck Squamous Cell Carcinoma (HNSCC)

Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma

Start date: November 1, 2023
Phase: N/A
Study type: Interventional

The enrolled head and neck squamous cell carcinoma patients in this study received high-dose multiday chemotherapy with cisplatin and synchronous radiation therapy, which had a high risk of nausea and vomiting. On the first and third days, they took Netopitam Palonosetron capsules and dexamethasone to reduce the incidence of acute vomiting. The aim of this study is to evaluate the antiemetic effect of Netopitam Palonosetron capsules and to explore the effectiveness of using Netopitam Palonosetron capsules again for antiemetic treatment during the study period when breakthrough vomiting occurs.

NCT ID: NCT06102161 Not yet recruiting - Lung Cancer Clinical Trials

Wedge Resection for Ground-glass Opacity-featured Lung Cancer (ECTOP-1020)

Start date: November 2023
Phase: Phase 3
Study type: Interventional

This is a clinical trial from the Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1020. The goal of this clinical trial is to confirm the therapeutic effect of Wedge resection for ground-glass opacity-featured lung cancer with a size less than 2cm and a consolidation-to-tumor ratio between 0.25 to 0.5.

NCT ID: NCT06101966 Not yet recruiting - Cervical Cancer Clinical Trials

A Predictive Model for Early Metastasis in Cervical Cancer Patients After Radiotherapy

Start date: December 1, 2023
Phase:
Study type: Observational

This study aims to help to screen out appropriate cases for consolidation therapy and more intensive follow up.

NCT ID: NCT06100328 Not yet recruiting - Cardiac Tumor Clinical Trials

Characteristics of Cardiac Tumor and the Risk Stratification of Subsequent Adverse Events (UNIQUE)

UNIQUE
Start date: September 1, 2024
Phase:
Study type: Observational

This study aims to retrospectively and prospectively collect clinical and biological specimen data from patients with cardiac tumors who meet the inclusion and exclusion criteria. Various techniques, including general molecular biology analysis and multi-omics analysis, will be used to construct a prognostic model for cardiac tumors.

NCT ID: NCT06099873 Not yet recruiting - Clinical trials for Respiratory Viral Infection

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of ZX-7101A Tablets to Evaluate the Efficacy and Safety in the Treatment of Uncomplicated Influenza in Adolescents

ZX-7101A-207
Start date: October 25, 2023
Phase: Phase 3
Study type: Interventional

The primary object of this study is evaluating the efficacy of ZX-7101A tablets versus placebo in the treatment of uncomplicated simple influenza in adolescents. The seongdary object is evaluating the safety of ZX-7101A tablet in the treatment of uncomplicated simple influenza in adolescents.

NCT ID: NCT06095167 Not yet recruiting - Clinical trials for Nasopharyngeal Carcinoma

Induction Chemotherapy and Immunotherapy Combined Radiotherapy With or Without Concurrent Chemotherapy for Stage III-IVa NPC

Start date: January 1, 2024
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare induction chemotherapy (gemcitabine+cisplatin) plus immunotherapy with concurrent chemoradiotherapy (CCRT) or RT alone in patients with stage III-IVa nasopharyngeal carcinoma(NPC), in order to confirm the value of Immunotherapy and concurrent chemotherapy in NPC patients.